Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: MS Clear all
Completed Not applicable Interventional

Outcomes of Group Dance and Movement Training in Ambulatory MS Patients

NCT05943145
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Group Dance and Movement Training
Other
Lead sponsor
GroundWorks DanceTheater
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jun 26, 2026, 6:35 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

NCT05156281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 26, 2026, 6:35 PM EDT
Terminated No phase listed Observational

Study of Diroximel Fumarate in the Real-World Setting

NCT04746976
View directory record Official record
Conditions
Relapsing Forms of MS
Interventions
Diroximel Fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
West Hollywood, California • Washington D.C., District of Columbia • Louisville, Kentucky + 15 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Jun 26, 2026, 6:35 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Patient Centered Outcomes Analysis for MS Using a Mobile Application

NCT04281160
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BeCare Mobile App
Device
Lead sponsor
BeCare Link LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Jun 26, 2026, 6:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Response in Treated MS Patients

NCT05060354
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
Blood draw
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Jun 26, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Results available

Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

NCT02760056
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Liothyronine sodium, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Jun 26, 2026, 6:35 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jun 26, 2026, 6:35 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis (SPMS)
Interventions
Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 6:35 PM EDT
Completed Not applicable Interventional

Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis

NCT02065284
View directory record Official record
Conditions
Multiple Sclerosis, Ambulation Difficulty
Interventions
Rhythmic Auditory Stimulation (RAS)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jun 26, 2026, 6:35 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

NCT00914758
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington Neuropsychology Research Group
Other
Eligibility
25 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Jun 26, 2026, 6:35 PM EDT
Terminated Phase 3 Interventional Results available

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

NCT00988052
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Laquinimod
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
20
States / cities
Phoenix, Arizona • Centennial, Colorado • Fort Collins, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jun 26, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT00355134
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
100
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Jun 26, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Results available

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

NCT03135249
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Alemtuzumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Jun 26, 2026, 6:35 PM EDT
Not yet recruiting No phase listed Observational

A Multi-Center Study Assessing the Safety and Efficacy of the LEGION Medial Stabilized (MS) Insert in Patients Undergoing a Total Knee Arthroplasty (TKA)

NCT07199738
View directory record Official record
Conditions
Inflammatory Arthritis, Primary Total Knee Arthroplasty Due to Degenerative Joint Disease (Primary Diagnosis of Osteoarthritis), Post-traumatic Arthritis
Interventions
Cemented CoCr, Cemented Oxinium, Cementless
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
6
States / cities
Phoenix, Arizona • Orlando, Florida • Newton, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 26, 2026, 6:35 PM EDT
Recruiting No phase listed Observational

A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

NCT06433765
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
No intervention
Other
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 26, 2026, 6:35 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

NCT01416181
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jun 26, 2026, 6:35 PM EDT
Completed Not applicable Interventional

The Use of Technology to Improve MS Clinical Trials and Patient Care

NCT02454907
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Communication with the clinic
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 26, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

NCT00649792
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
38
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jun 26, 2026, 6:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Protective Stepping in People With MS

NCT03551665
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Protective step training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jun 26, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Drug
Lead sponsor
Synthon BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jun 26, 2026, 6:35 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 26, 2026, 6:35 PM EDT
Terminated No phase listed Observational

Next-Gen MS: Feed-forward PRO Data for MS Research

NCT04907305
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Not listed
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jun 26, 2026, 6:35 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Identifying and Characterizing Preclinical MS

NCT05787795
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
biological samples
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2033
U.S. locations
1
States / cities
North Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 26, 2026, 6:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT05359653
View directory record Official record
Conditions
Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Benign
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 26, 2026, 6:35 PM EDT